Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Novel Immune Targets in Chronic Lymphocytic Leukemia: CD160 and IL-16 as Mediators of T Cell Exhaustion
EF 2025-26
Résumé
Chronic lymphocytic leukemia (CLL) is the most common blood cancer in adults in Western countries. Although modern treatments have improved outcomes, CLL remains incurable for most people and is often marked by repeated infections and weakened immune function. A major reason for this vulnerability is the gradual exhaustion of CD8 T cells, the immune cells that normally kill cancer and virus-infected cells. As exhaustion develops, these cells lose the ability to respond and carry out their protective roles. Our research suggests that certain inflammatory proteins found at high levels in people with CLL may drive this exhaustion. Two molecules in particular, IL-16 and CCL4, appear to disrupt the normal signals that keep T cells active. IL-16 increases an inhibitory molecule called CD160, while CCL4 reduces a stimulatory molecule called CD226. Together, these changes may weaken the ability of T cells to recognize and eliminate leukemic cells. However, the exact ways these cytokines contribute to immune failure in CLL remain unclear. This project will examine how IL-16 and CCL4 shape immune dysfunction in CLL. First, we will measure their levels in a large group of patients and determine how they relate to genetic features and disease severity. Next, we will study how these molecules alter T cell behaviour by analyzing changes in gene expression at the single-cell level. Finally, we will test whether blocking IL-16 or CD160 in a mouse model of CLL can restore immune activity and slow disease progression. By clarifying how chronic inflammation undermines T cell function, this research may help guide the development of new approaches that strengthen immune protection and improve long-term outcomes for people living with CLL.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572648
Name
Gopinath Gopesh
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Immune Targets in Chronic Lymphocytic Leukemia: CD160 and IL-16 as Mediators of T Cell Exhaustion
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cd8 T Cells; Chronic Lymphocytic Leukemia; Cytokine-Mediated Immune Suppression; Immune Modulation; Immunophenotyping; Inflammatory Microenvironment; Lymphoid Malignancies; Preclinical Immunotherapy; Single Cell Transcriptomics; T Cell Exhaustion
Abstract
Chronic lymphocytic leukemia (CLL) is the most common blood cancer in adults in Western countries. Although modern treatments have improved outcomes, CLL remains incurable for most people and is often marked by repeated infections and weakened immune function. A major reason for this vulnerability is the gradual exhaustion of CD8 T cells, the immune cells that normally kill cancer and virus-infected cells. As exhaustion develops, these cells lose the ability to respond and carry out their protective roles. Our research suggests that certain inflammatory proteins found at high levels in people with CLL may drive this exhaustion. Two molecules in particular, IL-16 and CCL4, appear to disrupt the normal signals that keep T cells active. IL-16 increases an inhibitory molecule called CD160, while CCL4 reduces a stimulatory molecule called CD226. Together, these changes may weaken the ability of T cells to recognize and eliminate leukemic cells. However, the exact ways these cytokines contribute to immune failure in CLL remain unclear. This project will examine how IL-16 and CCL4 shape immune dysfunction in CLL. First, we will measure their levels in a large group of patients and determine how they relate to genetic features and disease severity. Next, we will study how these molecules alter T cell behaviour by analyzing changes in gene expression at the single-cell level. Finally, we will test whether blocking IL-16 or CD160 in a mouse model of CLL can restore immune activity and slow disease progression. By clarifying how chronic inflammation undermines T cell function, this research may help guide the development of new approaches that strengthen immune protection and improve long-term outcomes for people living with CLL.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gopinath, Gopesh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~